{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:51:33Z","timestamp":1794307893159,"version":"4.9.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that can involve the bone marrow, peripheral blood, skin, lymph nodes, and the central nervous system. Though more common in older adults, BPDCN has been reported across all age groups, including infants and children. The incidence of pediatric BPDCN is extremely low and little is known about the disease. Pediatric BPDCN is believed to be clinically less aggressive but often with more dissemination at presentation than adult cases. Unlike adults who almost always proceed to a hematopoietic stem cell transplantation in first complete remission if transplant-eligible, the majority of children can be cured with a high-risk acute lymphoblastic leukemia-like regimen. Hematopoietic stem cell transplantation is recommended for children with high-risk disease, the definition of which continues to evolve, or those in relapse and refractory settings where outcomes continue to be dismal. Novel agents used in other hematologic malignancies and CD123 targeted agents, including chimeric antigen receptor T-cells and monoclonal\/bispecific antibodies, are being brought into research and practice. Our goal is to provide a comprehensive review of presentation, diagnosis, and treatment by review of pediatric cases reported for the last 20 years, and a review of novel targeted therapies and therapies under investigation for adult and pediatric patients.<\/jats:p>","DOI":"10.1038\/s41375-023-01968-z","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T08:02:08Z","timestamp":1689321728000},"page":"1767-1778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies"],"prefix":"10.1038","volume":"37","author":[{"given":"Branko","family":"Cuglievan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-8890","authenticated-orcid":false,"given":"Jeremy","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7479-4315","authenticated-orcid":false,"given":"Jiasen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3731-608X","authenticated-orcid":false,"given":"Sajad","family":"Khazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sireesha","family":"Yedururi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Garces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5304-7828","authenticated-orcid":false,"given":"Andres E.","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-2267","authenticated-orcid":false,"given":"Miriam","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2297-9670","authenticated-orcid":false,"given":"David","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-9404","authenticated-orcid":false,"given":"Dristhi","family":"Ragoonanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris M.","family":"Mahadeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Lamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pawlowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayatsu","family":"Senapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"1968_CR1","doi-asserted-by":"crossref","unstructured":"Wang W, Xu J, Khoury JD, Pemmaraju N, Fang H, Miranda RN, et al. Immunophenotypic and molecular features of acute myeloid leukemia with plasmacytoid dendritic cell differentiation are distinct from blastic plasmacytoid dendritic cell neoplasm. Cancers. 2022;14:3375.","DOI":"10.3390\/cancers14143375"},{"key":"1968_CR2","doi-asserted-by":"crossref","unstructured":"Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, et al. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2022;141:567\u201378.","DOI":"10.1182\/blood.2022017865"},{"key":"1968_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/asheducation-2016.1.16","volume":"2016","author":"JM Sullivan","year":"2016","unstructured":"Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematol Am Soc Hematol Educ Program. 2016;2016:16\u201323.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1968_CR4","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1002\/cncr.28930","volume":"120","author":"ME Rytting","year":"2014","unstructured":"Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, et al. Augmented Berlin-Frankfurt-M\u00fcnster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014;120:3660\u20138.","journal-title":"Cancer"},{"key":"1968_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000363434","volume":"132","author":"N Pemmaraju","year":"2014","unstructured":"Pemmaraju N, Cortes J. Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. Acta Haematol. 2014;132:298\u2013306.","journal-title":"Acta Haematol"},{"key":"1968_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.clml.2015.12.010","volume":"16","author":"N Pemmaraju","year":"2016","unstructured":"Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O'Brien S, et al. Patient characteristics and outcomes in adolescents and young adults (AYA) with acute myeloid leukemia (AML). Clin Lymphoma Myeloma Leuk. 2016;16:213\u2013e212.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1968_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11899-016-0313-6","volume":"11","author":"MA Perales","year":"2016","unstructured":"Perales MA, Drake EK, Pemmaraju N, Wood WA. Social media and the adolescent and young adult (AYA) patient with cancer. Curr Hematol Malig Rep. 2016;11:449\u201355.","journal-title":"Curr Hematol Malig Rep"},{"key":"1968_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ajh.24419","volume":"91","author":"ME Rytting","year":"2016","unstructured":"Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91:819\u201323.","journal-title":"Am J Hematol"},{"key":"1968_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00277-017-3165-9","volume":"97","author":"P Boddu","year":"2018","unstructured":"Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, et al. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018;97:109\u201321.","journal-title":"Ann Hematol"},{"key":"1968_CR10","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3324\/haematol.2010.026179","volume":"95","author":"AG Jegalian","year":"2010","unstructured":"Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95:1873\u20139.","journal-title":"Haematologica"},{"key":"1968_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1097\/00000478-199710000-00014","volume":"21","author":"JA DiGiuseppe","year":"1997","unstructured":"DiGiuseppe JA, Louie DC, Williams JE, Miller DT, Griffin CA, Mann RB, et al. Blastic natural killer cell leukemia\/lymphoma: a clinicopathologic study. Am J Surg Pathol. 1997;21:1223\u201330.","journal-title":"Am J Surg Pathol"},{"key":"1968_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","volume":"73","author":"GSG Murthy","year":"2018","unstructured":"Murthy GSG, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res. 2018;73:21\u20133.","journal-title":"Leuk Res"},{"key":"1968_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3324\/haematol.2012.072645","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239\u201346.","journal-title":"Haematologica"},{"key":"1968_CR14","first-page":"143","volume":"91","author":"AP Ng","year":"2006","unstructured":"Ng AP, Lade S, Rutherford T, McCormack C, Prince HM, Westerman DA. Primary cutaneous CD4+\/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases. Haematologica. 2006;91:143\u20134.","journal-title":"Haematologica"},{"key":"1968_CR15","first-page":"58","volume":"81","author":"C Bueno","year":"2004","unstructured":"Bueno C, Almeida J, Lucio P, Marco J, Garcia R, De Pablos JM, et al. Incidence and characteristics of CD4 (+)\/HLA DRhi dendritic cell malignancies. Haematologica. 2004;81:58\u201369.","journal-title":"Haematologica"},{"key":"1968_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjh.14146","volume":"174","author":"L Pagano","year":"2016","unstructured":"Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174:188\u2013202.","journal-title":"Br J Haematol"},{"key":"1968_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.path.2013.08.010","volume":"6","author":"KK Reichard","year":"2013","unstructured":"Reichard KK. Blastic plasmacytoid dendritic cell neoplasm: how do you distinguish it from acute myeloid leukemia? Surg Pathol Clin. 2013;6:743\u201365.","journal-title":"Surg Pathol Clin"},{"key":"1968_CR18","doi-asserted-by":"publisher","first-page":"S338","DOI":"10.1016\/S2152-2650(22)01461-6","volume":"22","author":"M Herling","year":"2022","unstructured":"Herling M, Deconinck E, Anant M, Manteigas D, Riggi M, Mughal T, et al. MPN-467 findings from an observational, multicenter, retrospective analysis of patients with blastic plasmacytoid dendritic cell neoplasm treated with Tagraxofusp in the European Expanded Access Program. Clin Lymphoma Myeloma Leuk. 2022;22:S338.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1968_CR19","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1080\/10428194.2021.1957878","volume":"62","author":"S El Hussein","year":"2021","unstructured":"El Hussein S, Wang W, Wang SA, Loghavi S, Wang X, Qiu L, et al. Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leuk Lymphoma. 2021;62:3296\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1968_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-018-0117-6","volume":"7","author":"K Chamoun","year":"2018","unstructured":"Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, et al. Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol. 2018;7:1\u20135.","journal-title":"Exp Hematol Oncol"},{"key":"1968_CR21","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/ajh.23567","volume":"88","author":"K Alayed","year":"2013","unstructured":"Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055\u201361.","journal-title":"Am J Hematol"},{"key":"1968_CR22","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1038\/s41375-021-01228-y","volume":"35","author":"K Batta","year":"2021","unstructured":"Batta K, Bossenbroek HM, Pemmaraju N, Wilks DP, Chasty R, Dennis M, et al. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia. 2021;35:3299\u2013303.","journal-title":"Leukemia"},{"key":"1968_CR23","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/jha2.525","volume":"3","author":"S El Hussein","year":"2022","unstructured":"El Hussein S, Yabe M, Wang W, Pemmaraju N, Loghavi S, Jelloul FZ, et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): an illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms. EJHaem. 2022;3:954\u20137.","journal-title":"EJHaem"},{"key":"1968_CR24","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/blood-2019-132185","volume":"134","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Kantarjian HM, Khoury JD, Loghavi S, O'Brien S, Cortes JE, et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) commonly presents in the setting of prior or concomitant hematologic malignancies (PCHM): patient characteristics and outcomes in the rapidly evolving modern targeted therapy era. Blood. 2019;134:2723.","journal-title":"Blood"},{"key":"1968_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/PAP.0b013e3181bb6bc2","volume":"16","author":"AG Jegalian","year":"2009","unstructured":"Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol. 2009;16:392.","journal-title":"Adv Anat Pathol"},{"key":"1968_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/BLCTT.S132060","volume":"7","author":"AM Trottier","year":"2017","unstructured":"Trottier AM, Cerquozzi S, Owen CJ. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects. Blood Lymphat Cancer. 2017;7:85\u201393.","journal-title":"Blood Lymphat Cancer"},{"key":"1968_CR27","doi-asserted-by":"crossref","unstructured":"Ziegler-Heitbrock L, Ohteki T, Ginhoux F, Shortman K, Spits H. Reclassifying plasmacytoid dendritic cells as innate lymphocytes. Nat Rev Immunol. 2023;23:1\u20132.","DOI":"10.1038\/s41577-022-00806-0"},{"key":"1968_CR28","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-cell RNA-Seq reveals aml hierarchies relevant to disease progression and immunity. Cell. 2019;176:1265\u201381.e1224.","journal-title":"Cell"},{"key":"1968_CR29","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1097\/PAS.0000000000001316","volume":"43","author":"N Sukswai","year":"2019","unstructured":"Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, et al. Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol. 2019;43:1429\u201337.","journal-title":"Am J Surg Pathol"},{"key":"1968_CR30","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","volume":"30","author":"M Ceribelli","year":"2016","unstructured":"Ceribelli M, Hou ZE, Kelly PN, Wright G, Ganapathi K, Evbuomwan MO, et al. A druggable TCF4-and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30:764\u201378.","journal-title":"Cancer Cell"},{"key":"1968_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","volume":"7","author":"J Montero","year":"2017","unstructured":"Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov. 2017;7:156\u201364.","journal-title":"Cancer Discov"},{"key":"1968_CR32","doi-asserted-by":"crossref","unstructured":"Wilson NR, Konopleva M, Khoury JD, Pemmaraju N. Novel therapeutic approaches in blastic plasmacytoid dendritic cell neoplasm (BPDCN): era of targeted therapy. Clin Lymphoma Myeloma Leukemia. 2021;21:734\u201340.","DOI":"10.1016\/j.clml.2021.05.018"},{"key":"1968_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/PAS.0b013e3181c5e26b","volume":"34","author":"C Cota","year":"2010","unstructured":"Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34:75\u201387.","journal-title":"Am J Surg Pathol"},{"key":"1968_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11899-018-0489-z","volume":"13","author":"JD Khoury","year":"2018","unstructured":"Khoury JD. Blastic plasmacytoid dendritic cell neoplasm. Curr Hematol Malig Rep. 2018;13:477\u201383.","journal-title":"Curr Hematol Malig Rep"},{"key":"1968_CR35","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn, Vol. 2. Lyon: International Agency for Research on Cancer, 2017."},{"key":"1968_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/cup.13099","volume":"45","author":"C Chu","year":"2018","unstructured":"Chu C, Rudnick EW, Motaparthi K. Blastic plasmacytoid dendritic cell neoplasm with centrocyte-like morphology clinically simulating a melanocytic nevus. J Cutan Pathol. 2018;45:249\u201353.","journal-title":"J Cutan Pathol"},{"key":"1968_CR37","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2020.247569","volume":"106","author":"W Wang","year":"2021","unstructured":"Wang W, Khoury JD, Miranda RN, Jorgensen JL, Xu J, Loghavi S, et al. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a ten-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2021;106:1047.","journal-title":"Haematologica"},{"key":"1968_CR38","unstructured":"Steven H, Swerdlow E, Harris N, Jaffe E, Pileri S, Stein H, et al. Who classification of tumours of haematopoietic and lymphoid tissues Revised 4th ed. Lyon: IARC; 2017."},{"key":"1968_CR39","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1084\/jem.194.12.1823","volume":"194","author":"A Dzionek","year":"2001","unstructured":"Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, et al. BDCA-2, a novel plasmacytoid dendritic cell\u2013specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon \u03b1\/\u03b2 induction. J Exp Med. 2001;194:1823\u201334.","journal-title":"J Exp Med"},{"key":"1968_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/10428194.2021.1975192","volume":"63","author":"NR Wilson","year":"2022","unstructured":"Wilson NR, Bover L, Konopleva M, Han L, Neelapu S, Pemmaraju N. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma. 2022;63:19\u201330.","journal-title":"Leuk Lymphoma"},{"key":"1968_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13039-016-0232-1","volume":"9","author":"Z Tang","year":"2016","unstructured":"Tang Z, Tang G, Wang SA, Lu X, Young KH, Bueso-Ramos CE, et al. Simultaneous deletion of 3\u2032 ETV6 and 5\u2032 EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Mol Cytogenet. 2016;9:1\u201310.","journal-title":"Mol Cytogenet"},{"key":"1968_CR42","doi-asserted-by":"crossref","unstructured":"Leroux D, Mugneret F, Callanan M, Radford-Weiss I, Dastugue N, Feuillard J, et al. CD4+, CD56+DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique. Blood, J Am Soc Hematol. 2002;99:4154\u20139.","DOI":"10.1182\/blood.V99.11.4154"},{"key":"1968_CR43","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/leu.2017.101","volume":"31","author":"K Suzuki","year":"2017","unstructured":"Suzuki K, Suzuki Y, Hama A, Muramatsu H, Nakatochi M, Gunji M, et al. Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2017;31:1629\u201333.","journal-title":"Leukemia"},{"key":"1968_CR44","doi-asserted-by":"publisher","first-page":"6404","DOI":"10.18632\/oncotarget.2223","volume":"5","author":"A Stenzinger","year":"2014","unstructured":"Stenzinger A, Endris V, Pfarr N, Andrulis M, J\u00f6hrens K, Klauschen F, et al. Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget. 2014;5:6404.","journal-title":"Oncotarget"},{"key":"1968_CR45","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood.V126.23.3746.3746","volume":"126","author":"N Pemmaraju","year":"2015","unstructured":"Pemmaraju N, Kantarjian HM, Cortes JE, Duvic M, Khoury JD, Patel K, et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a large single-center experience: analysis of clinical and molecular characteristics and patient outcomes. Blood. 2015;126:3746.","journal-title":"Blood"},{"key":"1968_CR46","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","volume":"12","author":"K Togami","year":"2022","unstructured":"Togami K, Chung SS, Madan V, Booth CA, Kenyon CM, Cabal-Hierro L, et al. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov. 2022;12:522\u201341.","journal-title":"Cancer Discov"},{"key":"1968_CR47","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s12185-020-03070-x","volume":"113","author":"C Liao","year":"2021","unstructured":"Liao C, Hu NX, Song H, Zhang JY, Shen DY, Xu XJ, et al. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature. Int J Hematol. 2021;113:751\u20139.","journal-title":"Int J Hematol"},{"key":"1968_CR48","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjd.12412","volume":"169","author":"F Julia","year":"2013","unstructured":"Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169:579\u201386.","journal-title":"Br J Dermatol"},{"key":"1968_CR49","doi-asserted-by":"publisher","first-page":"E140","DOI":"10.1002\/pbc.24622","volume":"60","author":"K Sakashita","year":"2013","unstructured":"Sakashita K, Saito S, Yanagisawa R, Tanaka M, Yoshikawa K, Hirabayashi K, et al. Usefulness of allogeneic hematopoietic stem cell transplantation in first complete remission for pediatric blastic plasmacytoid dendritic cell neoplasm with skin involvement: a case report and review of literature. Pediatr Blood Cancer. 2013;60:E140\u2013142.","journal-title":"Pediatr Blood Cancer"},{"key":"1968_CR50","doi-asserted-by":"crossref","unstructured":"Fanny A-D, Anne R, Arthur EF, Baptiste L, Estelle S, Sabeha B, et al. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica. 2015;100:223\u201330.","DOI":"10.3324\/haematol.2014.111740"},{"key":"1968_CR51","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","volume":"3","author":"F Garnache-Ottou","year":"2019","unstructured":"Garnache-Ottou F, Vidal C, Biichl\u00e9 S, Renosi F, Poret E, Pagadoy M, et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv. 2019;3:4238\u201351.","journal-title":"Blood Adv"},{"key":"1968_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ajh.2830470406","volume":"47","author":"M Adachi","year":"1994","unstructured":"Adachi M, Maeda K, Takekawa M, Hinoda Y, Imai K, Sugiyama S, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 1994;47:278\u201382.","journal-title":"Am J Hematol"},{"key":"1968_CR53","doi-asserted-by":"crossref","unstructured":"Davis JA, Rizzieri DA, Lane AA, Taylor J, Faisal MS, Vasu S, et al. Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Leuk Lymphoma. 2022;63:2757\u20139.","DOI":"10.1080\/10428194.2022.2090552"},{"key":"1968_CR54","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1182\/blood.2021011817","volume":"138","author":"N Pemmaraju","year":"2021","unstructured":"Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver N, Pierce S, et al. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021;138:1373\u20137.","journal-title":"Blood"},{"key":"1968_CR55","doi-asserted-by":"publisher","first-page":"10174","DOI":"10.18632\/oncotarget.7101","volume":"7","author":"L Mart\u00edn-Mart\u00edn","year":"2016","unstructured":"Mart\u00edn-Mart\u00edn L, Almeida J, Pomares H, Gonz\u00e1lez-Barca E, Bravo P, Gim\u00e9nez T, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7:10174.","journal-title":"Oncotarget"},{"key":"1968_CR56","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","volume":"4","author":"K Laribi","year":"2020","unstructured":"Laribi K, Baugier de Materre A, Sobh M, Cerroni L, Valentini CG, Aoki T, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv. 2020;4:4838\u201348.","journal-title":"Blood Adv"},{"key":"1968_CR57","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/ejh.12280","volume":"93","author":"M Starck","year":"2014","unstructured":"Starck M, Zewen S, Eigler A, Wendtner C-M. Meningeal spread of blastic plasmacytoid dendritic cell neoplasm. Eur J Haematol. 2014;93:175\u20136. 2014\/08\/01","journal-title":"Eur J Haematol"},{"key":"1968_CR58","doi-asserted-by":"crossref","unstructured":"Florescu AM, S\u00f8rensen ALT, Nielsen HV, Tolnai D, Sj\u00f6 LD, Larsen KL, et al. Blastic plasmacytoid dendritic cell neoplasm and cerebral toxoplasmosis: a case report. BMC Neurol. 2022;22:233.","DOI":"10.1186\/s12883-022-02748-5"},{"key":"1968_CR59","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.hoc.2020.01.008","volume":"34","author":"Y Li","year":"2020","unstructured":"Li Y, Sun V, Sun W, Pawlowska A. Blastic plasmacytoid dendritic cell neoplasm in children. Hematol\/Oncol Clin North Am. 2020;34:601\u201312.","journal-title":"Hematol\/Oncol Clin North Am"},{"key":"1968_CR60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/0284186X.2017.1420229","volume":"57","author":"P-Y Chou","year":"2018","unstructured":"Chou P-Y, Lai C-L, Huang P. Complete monocular vision loss due to optic nerve involvement of blastic plasmacytoid dendritic cell neoplasm. Acta Oncol. 2018;57:989\u201391.","journal-title":"Acta Oncol"},{"key":"1968_CR61","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(21)00161-7","volume":"8","author":"DA Balikov","year":"2021","unstructured":"Balikov DA, Bixby DL, Rao RC. Retinal haemorrhage as a complication of blastic plasmacytoid dendritic cell neoplasm. Lancet Haematol. 2021;8:e670.","journal-title":"Lancet Haematol"},{"key":"1968_CR62","unstructured":"Facchetti F, Petrella T. Blastic plasmacytoid dendritic cell neoplasm. Lyon: IARC Press; 2008."},{"key":"1968_CR63","unstructured":"Gurbuxani S. Blastic plasmacytoid dendritic cell neoplasm. UpToDate Post, TW, editor Waltham, MA: UpToDate 2015."},{"key":"1968_CR64","first-page":"3210","volume":"97","author":"L Chaperot","year":"2001","unstructured":"Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. J Am Soc Hematol. 2001;97:3210\u20137.","journal-title":"J Am Soc Hematol"},{"key":"1968_CR65","doi-asserted-by":"crossref","unstructured":"Facchetti FP, Pileri SA. Blastic plasmacytoid dendritic cell neoplasm. 4th edn. Lyon: IARC Press, 2016.","DOI":"10.1182\/asheducation-2016.1.16"},{"key":"1968_CR66","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/MPH.0000000000000964","volume":"39","author":"MJ Kim","year":"2017","unstructured":"Kim MJ, Nasr A, Kabir B, de Nanassy J, Tang K, Menzies-Toman D, et al. Pediatric blastic plasmacytoid dendritic cell neoplasm: a systematic literature review. J Pediatr Hematol Oncol. 2017;39:528\u201337.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1968_CR67","doi-asserted-by":"crossref","first-page":"205846011665768","DOI":"10.1177\/2058460116657688","volume":"5","author":"D Jeong","year":"2016","unstructured":"Jeong D, Choi JW, Jeong K, Sokol L. CT findings associated with blastic plasmacytoid dendritic cell neoplasm: a case report. Acta Radiol Open. 2016;5:2058460116657688.","journal-title":"Acta Radiol Open"},{"key":"1968_CR68","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.radcr.2021.07.010","volume":"16","author":"K Yoshioka","year":"2021","unstructured":"Yoshioka K, Kurokawa R, Amemiya S, Koyamaa H, Matsuda K, Honda A, et al. Rapidly progressing blastic plasmacytoid dendritic cell neoplasm causing diffuse skin thickening: a case report with sequential computed tomography examinations. Radiol Case Rep. 2021;16:2929\u201333.","journal-title":"Radiol Case Rep"},{"key":"1968_CR69","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/RLU.0000000000001159","volume":"41","author":"P Martineau","year":"2016","unstructured":"Martineau P, Pelletier-Galarneau M, Turpin S, Lambert R. Imaging pediatric plasmacytoid dendritic cell neoplasm with FDG PET\/CT: atypical presentation of a rare disease. Clin Nucl Med. 2016;41:426\u20137.","journal-title":"Clin Nucl Med"},{"key":"1968_CR70","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/jamaneurol.2015.0830","volume":"72","author":"WF Qubty","year":"2015","unstructured":"Qubty WF, Al-Kali A, Jones LK. Leukemic polyradiculopathy due to blastic plasmacytoid dendritic cell neoplasm. JAMA Neurol. 2015;72:938\u20139.","journal-title":"JAMA Neurol"},{"key":"1968_CR71","doi-asserted-by":"crossref","unstructured":"Castro DM, Su\u00e1rez OP, Cuervo-Sierra J, Moreno A. Blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report. Cureus. 2022;14:e23888.","DOI":"10.7759\/cureus.34549"},{"key":"1968_CR72","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4081\/rt.2014.5474","volume":"6","author":"H Saeed","year":"2014","unstructured":"Saeed H, Awasthi M, Al-Qaisi A, Massarweh S. Blastic plasmacytoid dendritic cell neoplasm with extensive cutaneous and central nervous system involvement. Rare Tumors. 2014;6:121\u20133.","journal-title":"Rare Tumors"},{"key":"1968_CR73","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00431-013-2248-4","volume":"173","author":"X-D Zhong","year":"2014","unstructured":"Zhong X-D, Wang L-Z, Wang X, et al. Lung metastases in a child with blastic plasmacytoid dendritic cell neoplasm and review. Eur J Pediatr. 2014;173:1667\u201370.","journal-title":"Eur J Pediatr"},{"key":"1968_CR74","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00277-012-1557-4","volume":"92","author":"K Endo","year":"2013","unstructured":"Endo K, Mihara K, Oiwa H, Yoshida T, Mino T, Sasaki N, et al. Lung involvement at initial presentation in blastic plasmacytoid dendritic cell neoplasm lacking cutaneous lesion. Ann Hematol. 2013;92:269.","journal-title":"Ann Hematol"},{"key":"1968_CR75","doi-asserted-by":"crossref","unstructured":"Lee SE, Park HY, Kwon D, Jeon YK, Kim WY. Blastic plasmacytoid dendritic cell neoplasm with unusual extracutaneous manifestation: two case reports and literature review. Medicine. 2019;98:e14344.","DOI":"10.1097\/MD.0000000000014344"},{"key":"1968_CR76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4274\/tjh.galenos.2018.2018.0181","volume":"36","author":"S Dhariwal","year":"2019","unstructured":"Dhariwal S, Gupta M. A case of blastic plasmacytoid dendritic cell neoplasm with unusual presentation. Turk J Hematol. 2019;36:55.","journal-title":"Turk J Hematol"},{"key":"1968_CR77","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/hon.2147","volume":"33","author":"R Paluri","year":"2015","unstructured":"Paluri R, Nabell L, Borak S, Peker D. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single\u2010center experience and literature review. Hematol Oncol. 2015;33:206\u201311.","journal-title":"Hematol Oncol"},{"key":"1968_CR78","first-page":"100313","volume":"17","author":"D Abla","year":"2022","unstructured":"Abla D, Abboud MR, Noun D, Tarek N, Pemmaraju N. Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): a case report and literature review. Leuk Res Rep. 2022;17:100313.","journal-title":"Leuk Res Rep"},{"key":"1968_CR79","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1586\/ehm.12.33","volume":"5","author":"PP Piccaluga","year":"2012","unstructured":"Piccaluga PP, Paolini S, Sapienza MR, Pileri SA. Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? Expert Rev Hematol. 2012;5:353\u20135.","journal-title":"Expert Rev Hematol"},{"key":"1968_CR80","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1002\/pbc.24483","volume":"60","author":"KD Wright","year":"2013","unstructured":"Wright KD, Onciu MM, Coustan-Smith E, Campana D, Raimondi SC, Inaba H, et al. Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:E38\u2013E41.","journal-title":"Pediatr Blood Cancer"},{"key":"1968_CR81","doi-asserted-by":"crossref","unstructured":"Cesarman-Maus G, Lome C, Espinosa KA, Quezada-Fiallos CM, Rivas S, Quezda R. Clinical and pathological features and differential diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN): a series of cases. Blood. 2016;128:5183.","DOI":"10.1182\/blood.V128.22.5183.5183"},{"key":"1968_CR82","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3892\/etm.2015.2236","volume":"9","author":"N Gao","year":"2015","unstructured":"Gao N, Wang XX, Sun JR, Yu WZ, Guo NJ. Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: a case report. Exp Ther Med. 2015;9:1109\u201312.","journal-title":"Exp Ther Med"},{"key":"1968_CR83","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","volume":"95","author":"J Feuillard","year":"2002","unstructured":"Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;95:1556\u201363.","journal-title":"Blood"},{"key":"1968_CR84","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.3324\/haematol.11307","volume":"92","author":"H Stephen Chu-Sung","year":"2007","unstructured":"Stephen Chu-Sung H, Kun-Bow T, Gwo-Shing C, Po-Hung C. Infantile CD4+\/CD56+ hematodermic neoplasm. Haematologica. 2007;92:e91\u2013e93.","journal-title":"Haematologica"},{"key":"1968_CR85","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/MPH.0b013e31819b7215","volume":"31","author":"A Hama","year":"2009","unstructured":"Hama A, Kudo K, Itzel BV, Muramatsu H, Nishio N, Yoshida N, et al. Plasmacytoid dendritic cell leukemia in children. J Pediatr Hematol\/Oncol. 2009;31:339\u201343.","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"1968_CR86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41409-021-01478-5","volume":"57","author":"Q Bashir","year":"2022","unstructured":"Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, et al. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transpl. 2022;57:51\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"1968_CR87","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.","journal-title":"JAMA Oncol"},{"key":"1968_CR88","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/1097-0142(20010215)91:4<642::AID-CNCR1047>3.0.CO;2-2","volume":"91","author":"PH Shaw","year":"2001","unstructured":"Shaw PH, Cohn SL, Morgan ER, Kovarik P, Haut PR, Kletzel M, et al. Natural killer cell lymphoma: report of two pediatric cases, therapeutic options, and review of the literature. Cancer. 2001;91:642\u20136.","journal-title":"Cancer"},{"key":"1968_CR89","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1097\/00000478-200310000-00009","volume":"27","author":"K Karube","year":"2003","unstructured":"Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Suefuji H, Suzumiya J, et al. Non-B, Non-T neoplasms with lymphoblast morphology: further clarification and classification. Am J Surg Pathol. 2003;27:1366\u201374.","journal-title":"Am J Surg Pathol"},{"key":"1968_CR90","first-page":"ECR48","volume":"9pl","author":"A Ruggiero","year":"2006","unstructured":"Ruggiero A, Maurizi P, Larocca LM, Arlotta A, Riccardi R. Childhood CD4+\/CD56+ hematodermic neoplasm: case report and review of the literature. Haematologica. 2006;9pl:ECR48.","journal-title":"Haematologica"},{"key":"1968_CR91","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1309\/W9Q5AGYDE5LANN39","volume":"123","author":"ME Pilichowska","year":"2007","unstructured":"Pilichowska ME, Fleming MD, Pinkus JL, Pinkus GS. CD4+\/CD56+ hematodermic neoplasm (\"blastic natural killer cell lymphoma\"): Neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol. 2007;123:445\u201353.","journal-title":"Am J Clin Pathol"},{"key":"1968_CR92","doi-asserted-by":"crossref","unstructured":"Livio P, Caterina Giovanna V, Alessandro P, Simona F, Paola C, Francesco M, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239\u201346.","DOI":"10.3324\/haematol.2012.072645"},{"key":"1968_CR93","doi-asserted-by":"publisher","first-page":"19204","DOI":"10.18632\/oncotarget.4146","volume":"6","author":"L Mart\u00edn-Mart\u00edn","year":"2015","unstructured":"Mart\u00edn-Mart\u00edn L, L\u00f3pez A, Vidriales B, Caballero MD, Rodrigues AS, Ferreira SI, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget. 2015;6:19204.","journal-title":"Oncotarget"},{"key":"1968_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-2-4","volume":"2","author":"U Testa","year":"2014","unstructured":"Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2:4.","journal-title":"Biomark Res"},{"key":"1968_CR95","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/10428190701799035","volume":"49","author":"A Frankel","year":"2008","unstructured":"Frankel A, Liu J-S, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk lymphoma. 2008;49:543\u201353.","journal-title":"Leuk lymphoma"},{"key":"1968_CR96","first-page":"3942","volume":"122","author":"D Fanny","year":"2013","unstructured":"Fanny D, Frankel AE, Seilles E, Biichle S, Deconninck E, Bonnefoy F, et al. Preclinical studies of SL-401, a targeted therapy directed to the interleukin-3 receptor (IL3-R), in blastic plasmacytoid dendritic cell neoplasm (BPDCN): potent activity in BPDCN cell lines, primary tumor, and in an in vivo model. Blood. 2013;122:3942.","journal-title":"Blood"},{"key":"1968_CR97","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380:1628\u201337.","journal-title":"N Engl J Med"},{"key":"1968_CR98","doi-asserted-by":"crossref","unstructured":"Frankel AE, Konopleva M, Hogge D, Rizzieri D, Brooks C, Cirrito T, et al. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. Blood. 2014;124:385\u201392.","DOI":"10.1200\/jco.2013.31.15_suppl.7029"},{"key":"1968_CR99","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","volume":"124","author":"AE Frankel","year":"2014","unstructured":"Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124:385\u201392.","journal-title":"Blood"},{"key":"1968_CR100","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-018-0604-6","volume":"11","author":"W Sun","year":"2018","unstructured":"Sun W, Liu H, Kim Y, Karras N, Pawlowska A, Toomey D, et al. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. J Hematol Oncol. 2018;11:61.","journal-title":"J Hematol Oncol"},{"key":"1968_CR101","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2021-150393","volume":"138","author":"N Pemmaraju","year":"2021","unstructured":"Pemmaraju N, Cuglievan B, Lasky JL III, Kheradpour A, Hijiya N, Stein AS, et al. Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in pediatric patients with Tagraxofusp, a CD123-targeted therapy. Blood. 2021;138:2317.","journal-title":"Blood"},{"key":"1968_CR102","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/leu.2014.64","volume":"28","author":"M Sapienza","year":"2014","unstructured":"Sapienza M, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra M, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014;28:1606\u201316.","journal-title":"Leukemia"},{"key":"1968_CR103","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fonc.2018.00636","volume":"8","author":"CM Adams","year":"2019","unstructured":"Adams CM, Clark-Garvey S, Porcu P, Eischen CM. Targeting the Bcl-2 family in B cell lymphoma. Front Oncol. 2019;8:636.","journal-title":"Front Oncol"},{"key":"1968_CR104","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","volume":"26","author":"S Jin","year":"2020","unstructured":"Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN, Xiao Y, et al. 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res. 2020;26:3371\u201383.","journal-title":"Clin Cancer Res"},{"key":"1968_CR105","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1968_CR106","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311\u201322.","journal-title":"N Engl J Med"},{"key":"1968_CR107","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL 2\u2010inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93:401\u20137.","journal-title":"Am J Hematol"},{"key":"1968_CR108","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMc1808354","volume":"379","author":"ME Agha","year":"2018","unstructured":"Agha ME, Monaghan SA, Swerdlow SH. Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2018;379:1479\u201381.","journal-title":"N Engl J Med"},{"key":"1968_CR109","doi-asserted-by":"crossref","unstructured":"Grushchak S, Joy C, Gray A, Opel D, Speiser J, Reserva J, et al. Novel treatment of blastic plasmacytoid dendritic cell neoplasm: a case report. Medicine. 2017;96:e9452.","DOI":"10.1097\/MD.0000000000009452"},{"key":"1968_CR110","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12288-020-01313-9","volume":"37","author":"Z Narli Ozdemir","year":"2021","unstructured":"Narli Ozdemir Z, Cengiz Seval G, Sahin U, Uslu A, Gunduz M, Civriz Bozdag S, et al. Blastic plasmacytoid dendritic cell neoplasm: single center experience on a rare hematological malignancy. Indian J Hematol Blood Transfus. 2021;37:67\u201375.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"1968_CR111","doi-asserted-by":"publisher","first-page":"E62","DOI":"10.1002\/ajh.26417","volume":"97","author":"N Gangat","year":"2022","unstructured":"Gangat N, Konopleva M, Patnaik MM, Jabbour E, DiNardo C, Al-Kali A, et al. Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2022;97:E62\u2013E67.","journal-title":"Am J Hematol"},{"key":"1968_CR112","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2020.01.007","volume":"34","author":"AA Lane","year":"2020","unstructured":"Lane AA. Novel therapies for blastic plasmacytoid dendritic cell neoplasm. Hematol\/Oncol Clin. 2020;34:589\u2013600.","journal-title":"Hematol\/Oncol Clin"},{"key":"1968_CR113","doi-asserted-by":"crossref","unstructured":"Pemmaraju N, Konopleva M. More on blastic plasmacytoid dendritic-cell neoplasms. N Engl J Med. 2019;380:695\u20137.","DOI":"10.1056\/NEJMc1814963"},{"key":"1968_CR114","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1172\/JCI128571","volume":"129","author":"K Togami","year":"2019","unstructured":"Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Investig. 2019;129:5005\u201319.","journal-title":"J Clin Investig"},{"key":"1968_CR115","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1182\/blood-2021-147486","volume":"138","author":"AA Lane","year":"2021","unstructured":"Lane AA, Stein AS, Garcia JS, Garzon JL, Galinsky I, Luskin MR. et al. Safety and efficacy of combining Tagraxofusp (SL-401) with azacitidine or azacitidine and venetoclax in a phase 1b study for CD123 positive AML, MDS, or BPDCN. Blood. 2021;138:2346.","journal-title":"Blood"},{"key":"1968_CR116","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1182\/bloodadvances.2019000173","volume":"4","author":"N Pemmaraju","year":"2020","unstructured":"Pemmaraju N, Konopleva M. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020;4:4020\u20137.","journal-title":"Blood Adv"},{"key":"1968_CR117","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3324\/haematol.2018.205252","volume":"104","author":"E Angelova","year":"2019","unstructured":"Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, et al. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019;104:749.","journal-title":"Haematologica"},{"key":"1968_CR118","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","volume":"2","author":"Y Kovtun","year":"2018","unstructured":"Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2:848\u201358.","journal-title":"Blood Adv"},{"key":"1968_CR119","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-139903","volume":"136","author":"N Pemmaraju","year":"2020","unstructured":"Pemmaraju N, Martinelli G, Todisco E, Lane AA, Acu\u00f1a-Cruz E, Deconinck E, et al. Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2020;136:11\u20133.","journal-title":"Blood"},{"key":"1968_CR120","doi-asserted-by":"crossref","unstructured":"B\u00f4le-Richard E, Pemmaraju N, Ca\u00ebl B, Daguindau E, Lane AA. CD123 and more: how to target the cell surface of blastic plasmacytoid dendritic cell neoplasm. Cancers. 2022;14:2287.","DOI":"10.3390\/cancers14092287"},{"key":"1968_CR121","doi-asserted-by":"publisher","first-page":"106928","DOI":"10.1016\/j.leukres.2022.106928","volume":"121","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, et al. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): clinicopathological insights. Leuk Res. 2022;121:106928.","journal-title":"Leuk Res"},{"key":"1968_CR122","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.omtm.2020.06.024","volume":"18","author":"JM Riberdy","year":"2020","unstructured":"Riberdy JM, Zhou S, Zheng F, Kim Y-I, Moore J, Vaidya A, et al. The art and science of selecting a CD123-specific chimeric antigen receptor for clinical testing. Mol Ther\u2014Methods Clin Dev. 2020;18:571\u201381.","journal-title":"Mol Ther\u2014Methods Clin Dev"},{"key":"1968_CR123","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2022-170956","volume":"140","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Kantarjian H, Khoury JD, Jain N, Qazilbash MH, Loghavi S. et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): long-term outcomes and novel observations from a large BPDCN cohort. Blood. 2022;140:1293\u20134.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01968-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01968-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01968-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T04:20:29Z","timestamp":1729743629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01968-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":123,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1968"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01968-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]},"assertion":[{"value":"22 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}